doi:10.3969/j.issn.1673-8640.2024.05.018

Abstract

CLC Number:

R446.11

Figures/Tables 6

References 23

[1]	中国研究型医院学会血栓与止血专委会. 活化部分凝血活酶时间延长混合血浆纠正试验操作流程及结果解读中国专家共识[J]. 中华检验医学杂志, 2021, 44(8):690-697.
[2]	COLLINS P W, CHALMERS E, HART D P, et al. Diagnosis and treatment of factor Ⅷ andⅨ inhibitors in congenital haemophilia:(4th edition)[J]. Br J Haematol, 2013, 160(2):153-170.
[3]	MIYAKIS S, LOCKSHIN M D, ATSUMI T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome(APS)[J]. J Thromb Haemost, 2006, 4(2):295-306.
[4]	AMES P R, GRAF M, ARCHER J, et al. Prolonged activated partial thromboplastin time:difficulties in discriminating coexistent factorⅧ inhibitor and lupus anticoagulant[J]. Clin Appl Thromb Hemost, 2015, 21(2):149-154.
[5]	王佰言, 张磊, 王琰, 等. 获得性凝血因子Ⅴ缺乏合并血小板功能障碍的病例研究并文献复习[J]. 血栓与止血学, 2023, 29(1):37-40.
[6]	中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 凝血因子Ⅷ/Ⅸ抑制物诊断与治疗中国指南(2018年版)[J]. 中华血液学杂志, 2018, 39(10):793-799.
[7]	赵久良, 沈海丽, 柴克霞, 等. 抗磷脂综合征诊疗规范[J]. 中华内科杂志, 2022, 61(9):1000-1007.
[8]	颜楠, 韩峰, 刁艳君, 等. 采用稀释法评价狼疮抗凝物对凝血因子活性检测的干扰[J]. 检验医学与临床, 2021, 18(24):3588-3590.
[9]	GARDINER C, COLEMAN R, DE MAAT MPM, et al. International Council for Standardization in Haematology(ICSH)aboratory guidance for the verification of haemostasis analyser-reagent test systems. Part 2:specialist tests and calibrated assays[J]. Int J Lab Hematol, 2021, 43(5):907-916.
[10]	FRANCHINI M, LIPPI G. Acquired factor Ⅴ inhibitors:a systematic review[J]. J Thromb Thrombolysis, 2011, 34(4):449-457.
[11]	WANG X, QIN X, YU Y, et al. Acquired factor Ⅴ deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor Ⅴ inhibitor:a case report and review of the literature[J]. Blood Coagul Fibrinolysis, 2017, 28(4):334-341.
[12]	WIWANITKIT V. Spectrum of bleeding in acquired factor Ⅴ inhibitor:a summary of 33 cases[J]. Clin Appl Thromb Hemost, 2006, 12(4):485.
[13]	GOULENOK T, VASCO C, FAILLE D, et al. Acquired factor Ⅴ inhibitor:a nation-wide study of 38 patients[J]. Br J Haematol, 2021, 192(5):892-899.
[14]	ICHINOSE A, OSAKI T, SOURI M, et al. A review of coagulation abnormalities of autoimmune acquired factor Ⅴ deficiency with a focus on Japan[J]. Semin Thromb Hemost, 2022, 48(2):206-218.
[15]	SRIDHARAN M, FYLLING K A, ASHRANI A A, et al. Clinical and laboratory diagnosis of autoimmune factor Ⅴ inhibitors:a single institutional experience[J]. Thrombosis Research, 2018, 171:14-21.
[16]	尚阳丽, 钟光彩, 李世洁, 等. 31例获得性凝血因子缺乏症的回顾性分析[J]. 山东大学学报(医学版), 2023, 61(5):25-30.
[17]	OLSON N J, ORNSTEIN D L. Factor Ⅴ inhibitors:a diagnostic and therapeutic challenge[J]. Arch Pathol Lab Med, 2017, 141(12):1728-1731.
[18]	ANG A L, KUPERAN P, NG C H, et al. Acquired factor Ⅴ inhibitor. A problem-based systematic review[J]. T Thromb Haemost, 2009, 101(5):852-859.
[19]	FAVALORO E J, POSEN J, RAMAKRISHNA R, et al. Factor Ⅴ inhibitors:rare or not so uncommon?A multi-laboratory investigation[J]. Blood Coagul Fibrinolysis, 2004, 15(8):637-647.
[20]	STREIFF M B, NESS P M. Acquired FⅤ inhibitors:a needless iatrogenic complication of bovine thrombin exposure[J]. Transfusion, 2002, 42(1):18-26.
[21]	MOTWANI P, HOWARD L, ALI S S. Successful management of a possible antibiotic-related acquired factor Ⅴ inhibitor:a case report and review of the literature[J]. Acta Haematol, 2013, 129(3):182-184.
[22]	陈云飞, 刘葳, 刘晓帆, 等. 获得性凝血因子Ⅴ缺乏症的临床诊治[J]. 中国临床医学, 2017, 24(2):260-264.
[23]	MOORE G W. Lupus anticoagulant testing:dilute prothrombin time(dPT)[J]. Methods Mol Biol, 2023, 2663:275-288.

项目	结果	参考区间
PT	55.1 s	10.0~15.0 s
国际标准化比值	5.15
APTT	74.6 s	25.0~31.3 s
凝血酶时间	18.0 s	13.0~21.0 s
纤维蛋白原	3.7 g·L^-1	2.0~4.0 g·L^-1
D-二聚体	0.37 mg·L^-1	0~0.50 mg·L^-1

项目	结果	参考区间
PT	55.1 s	10.0~15.0 s
国际标准化比值	5.15
APTT	74.6 s	25.0~31.3 s
凝血酶时间	18.0 s	13.0~21.0 s
纤维蛋白原	3.7 g·L^-1	2.0~4.0 g·L^-1
D-二聚体	0.37 mg·L^-1	0~0.50 mg·L^-1

纠正试验	结果	参考区间
PT纠正试验
正常血浆	11.0 s	10.0~15.0 s
患者血浆	55.1 s	10.0~15.0 s
混合后即刻血浆	25.4 s
PT-Rosner指数	26.0%	*
APTT纠正试验
正常血浆	26.8 s	25.0~31.3 s
患者血浆	95.2 s	25.0~31.3 s
混合后即刻血浆	34.8 s
APTT-Rosner指数	8.4%	*
混合后孵育	44.7 s
孵育后混合	35.0 s
混合后孵育-孵育后混合（Δ）	9.7 s	*

纠正试验	结果	参考区间
PT纠正试验
正常血浆	11.0 s	10.0~15.0 s
患者血浆	55.1 s	10.0~15.0 s
混合后即刻血浆	25.4 s
PT-Rosner指数	26.0%	*
APTT纠正试验
正常血浆	26.8 s	25.0~31.3 s
患者血浆	95.2 s	25.0~31.3 s
混合后即刻血浆	34.8 s
APTT-Rosner指数	8.4%	*
混合后孵育	44.7 s
孵育后混合	35.0 s
混合后孵育-孵育后混合（Δ）	9.7 s	*

项目	初次检测		混合纠正
项目	结果	参考区间	结果	参考区间
LA筛查时间（LA1）	201.2 s	31.0~44.0 s	75.5 s	31.0~44.0 s
LA筛查比值	5.38		2.02
LA确诊时间（LA2）	128.0 s	30.0~38.0 s	64.3 s	30.0~38.0 s
LA确诊比值	4.13		2.07
LA1/LA2	1.30	0.80~1.20	0.97	0.80~1.20

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 23

Related Articles 15

Recommended Articles

Metrics

项目	原倍	稀释4倍	稀释8倍	参考区间
凝血因子Ⅱ	74.5	79.6	86.5	81.0~114.4
凝血因子Ⅴ	2.0	低于下限	低于下限	71.5~133.3
凝血因子Ⅶ	76.1	90.3	106.9	85.7~120.3
凝血因子Ⅷ	170.7	未检测	未检测	77.3~128.7
凝血因子Ⅸ	87.0	未检测	未检测	67.7~128.5
凝血因子Ⅹ	75.3	83.5	90.5	84.0~122.0
凝血因子Ⅺ	101.2	未检测	未检测	81.6~118.4
凝血因子Ⅻ	47.2	未检测	未检测	50.0~120.0
血管性血友病因子	191.6	未检测	未检测	49.5~187.0

项目	结果/（BU·mL^-1）	参考值/（BU·mL^-1）
凝血因子Ⅷ抑制物滴度	<0.6	<0.6
凝血因子Ⅴ抑制物滴度	5.9	<0.6

项目	结果	参考值	单位
抗β2糖蛋白Ⅰ抗体IgA/IgG/IgM	7.6	<20.0	RU·mL^-1
抗心磷脂抗体IgA/IgG/IgM	1.2	<12.0	RU·mL^-1
抗心磷脂抗体IgG	0.4	<12.0	GPL-U·mL^-1
抗心磷脂抗体IgM	1.0	<12.0	MPL-U·mL^-1

[1]	ZHOU Ruiling, ZHANG Xinyu, REN Xiaoling, ZHANG Wen, FAN Changzheng, ZHANG Qiong. Relationship between uric acid/creatinine ratio and neutrophil/lymphocyte ratio and hypoxemia in patients with acute exacerbation of chronic obstructive pulmonary disease [J]. Laboratory Medicine, 2024, 39(5): 474-479.
[2]	LI Kejing, WANG Lin, YANG Ning. Relationship between NLR，TGF-β1 and Cav-1 levels and bleeding risk after mechanical thrombectomy for acute intracranial artery occlusion in elders [J]. Laboratory Medicine, 2024, 39(5): 480-484.
[3]	LIU Lin, WANG Tiankai, QIN Kangchunfeng, DING Ning. Correlations between monocyte-to-lymphocyte ratio with coronary heart disease and the extent of coronary atherosclerosis [J]. Laboratory Medicine, 2024, 39(5): 485-490.
[4]	WANG Xuexing, CHEN Chunmei, HE Yuan, CHU Jie, WEI Chunmei. Roles of thromboelastography and coagulation index in predicting venous thromboembolism in patients with tumors [J]. Laboratory Medicine, 2024, 39(5): 491-496.
[5]	XIONG Tianhui, CHAI Kening, XIA Wei, QU Linlin. Research progress of rivaroxaban causing changes in platelet count and function [J]. Laboratory Medicine, 2024, 39(5): 504-509.
[6]	HUANG Lei, TANG Wenjia, ZHOU Yan, ZHOU Jiaye, ZHANG Chunyan, YANG Jing, WANG Beili, PAN Baishen, GUO wei. Prognosis of RDW-SD and RDW-CV in breast cancer patients with lymphatic metastasis [J]. Laboratory Medicine, 2024, 39(4): 376-381.
[7]	. [J]. Laboratory Medicine, 2024, 39(1): 68-70.
[8]	DENG Chenxia, MEI Yanping, ZHANG Xia, HUANG Baoshan, TIAN Dan, CAO Mengting, HU Yongqi, LIN Yongping, TIAN Lijun. Depolymerization effect of optical platelet count on reversible platelet aggregation after blood collection [J]. Laboratory Medicine, 2023, 38(11): 1087-1090.
[9]	LU Tingyan, GU Danfeng, WANG Yahong, GE Yafang, YANG Haiou. Evaluation of vaginal secretion routine determination modes and review criteria analysis [J]. Laboratory Medicine, 2023, 38(11): 1091-1097.
[10]	. [J]. Laboratory Medicine, 2023, 38(11): 1098-1100.
[11]	. [J]. Laboratory Medicine, 2023, 38(10): 983-986.
[12]	. [J]. Laboratory Medicine, 2023, 38(9): 901-904.
[13]	. [J]. Laboratory Medicine, 2023, 38(9): 905-908.
[14]	CHENG Xu, YANG Cunqing, PANG Bo, GU Chun, HOU Xueyun, FEI Jiaxin, WU Min, LI Jun, LIU Guijian. Number and activity of peripheral blood eosinophils in obese people [J]. Laboratory Medicine, 2023, 38(9): 855-859.
[15]	LEI Jing, MAN Qiuhong, ZHAO Renjia, ZHANG Tiejun, JIANG Yanfeng, XU Kelin, SUO Chen, CHEN Xingdong. Elevated red blood cell distribution width increasing the risk of heart failure：a cohort study based on the UK Biobank [J]. Laboratory Medicine, 2023, 38(9): 860-864.